AMAchim K. Moesta

Achim K. Moesta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Achim K. Moesta has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures from Control of Metastases via Myeloid CD39 and NK Cell Effector Function

    by Juming Yan, Xian-Yang Li, Amelia Roman Aguilera, Christos Xiao, Celia Jacoberger-Foissac, Bianca Nowlan, Simon C. Robson, Courtney Beers, Achim K. Moesta, Nishamol Geetha, et al.

  • Open Access

    Supplementary Figures from Control of Metastases via Myeloid CD39 and NK Cell Effector Function

    by Juming Yan, Xian-Yang Li, Amelia Roman Aguilera, Christos Xiao, Celia Jacoberger-Foissac, Bianca Nowlan, Simon C. Robson, Courtney Beers, Achim K. Moesta, Nishamol Geetha, et al.

    Supplementary Figures 1-10 + Legends

  • Open Access

    Data from Control of Metastases via Myeloid CD39 and NK Cell Effector Function

    by Juming Yan, Xian-Yang Li, Amelia Roman Aguilera, Christos Xiao, Celia Jacoberger-Foissac, Bianca Nowlan, Simon C. Robson, Courtney Beers, Achim K. Moesta, Nishamol Geetha, et al.

    Natural killer (NK) cell protection from tumor metastases is a critical feature of the host immune response to cancer, but various immunosuppression mechanisms limit NK cell effector function. The ectoenzyme, CD39, expressed on tumor-infiltrating myeloid cells, granulocytes, and lymphocytes, including NK cells, converts extracellular ATP (eATP) into AMP and, thus, potentially suppresses eATP-mediated proinflammatory responses. A CD39-targeting monoclonal antibody (mAb) that inhibits the mouse ectoenzyme CD39 suppressed experimental and spontaneous metastases in a number of different tumor models and displayed superior antimetastatic activity compared with the CD39 inhibitor POM1 and inhibitors and mAbs that block other members of the adenosinergic family (e.g., A2AR and CD73). The antimetastatic activity of anti-CD39 was NK cell and IFNγ dependent, and anti-CD39 enhanced the percentage and quantity of IFNγ produced and CD107a expression in lung-infiltrating NK cells following tumor challenge and anti-CD39 therapy. Using conditional Cd39 gene–targeted mouse strains and adoptive NK cell transfers, we showed that CD39 expressed on bone marrow–derived myeloid cells was essential for anti-CD39′s antimetastatic activity, but NK cell expression of CD39 was not critical. The eATP receptor P2X7 and the NALP3 inflammasome, including downstream IL18, were critical in the mechanism of action of anti-CD39, and the frequency of P2X7 and CD39 coexpressing lung alveolar macrophages was specifically reduced 1 day after anti-CD39 therapy. The data provide a mechanism of action involving NK cells and myeloid cells, and anti-CD39 combined with anti–PD-1, NK cell–activating cytokines IL15 or IL2, or an inhibitor of A2AR to effectively suppress tumor metastases.

  • Open Access

    Data from Control of Metastases via Myeloid CD39 and NK Cell Effector Function

    by Juming Yan, Xian-Yang Li, Amelia Roman Aguilera, Christos Xiao, Celia Jacoberger-Foissac, Bianca Nowlan, Simon C. Robson, Courtney Beers, Achim K. Moesta, Nishamol Geetha, et al.

    Natural killer (NK) cell protection from tumor metastases is a critical feature of the host immune response to cancer, but various immunosuppression mechanisms limit NK cell effector function. The ectoenzyme, CD39, expressed on tumor-infiltrating myeloid cells, granulocytes, and lymphocytes, including NK cells, converts extracellular ATP (eATP) into AMP and, thus, potentially suppresses eATP-mediated proinflammatory responses. A CD39-targeting monoclonal antibody (mAb) that inhibits the mouse ectoenzyme CD39 suppressed experimental and spontaneous metastases in a number of different tumor models and displayed superior antimetastatic activity compared with the CD39 inhibitor POM1 and inhibitors and mAbs that block other members of the adenosinergic family (e.g., A2AR and CD73). The antimetastatic activity of anti-CD39 was NK cell and IFNγ dependent, and anti-CD39 enhanced the percentage and quantity of IFNγ produced and CD107a expression in lung-infiltrating NK cells following tumor challenge and anti-CD39 therapy. Using conditional Cd39 gene–targeted mouse strains and adoptive NK cell transfers, we showed that CD39 expressed on bone marrow–derived myeloid cells was essential for anti-CD39′s antimetastatic activity, but NK cell expression of CD39 was not critical. The eATP receptor P2X7 and the NALP3 inflammasome, including downstream IL18, were critical in the mechanism of action of anti-CD39, and the frequency of P2X7 and CD39 coexpressing lung alveolar macrophages was specifically reduced 1 day after anti-CD39 therapy. The data provide a mechanism of action involving NK cells and myeloid cells, and anti-CD39 combined with anti–PD-1, NK cell–activating cytokines IL15 or IL2, or an inhibitor of A2AR to effectively suppress tumor metastases.

  • Open Access

    Supplementary Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity

    by Xian-Yang Li, Achim K. Moesta, Christos Xiao, Kyohei Nakamura, Mika Casey, Haiyan Zhang, Jason Madore, Ailin Lepletier, Amelia Roman Aguilera, Ashmitha Sundarrajan, et al.

  • Open Access

    Supplementary Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity

    by Xian-Yang Li, Achim K. Moesta, Christos Xiao, Kyohei Nakamura, Mika Casey, Haiyan Zhang, Jason Madore, Ailin Lepletier, Amelia Roman Aguilera, Ashmitha Sundarrajan, et al.

    Supplementary Methods, Figures, Legends and Tables

  • Open Access

    Data from Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity

    by Xian-Yang Li, Achim K. Moesta, Christos Xiao, Kyohei Nakamura, Mika Casey, Haiyan Zhang, Jason Madore, Ailin Lepletier, Amelia Roman Aguilera, Ashmitha Sundarrajan, et al.

    We explored the mechanism of action of CD39 antibodies that inhibit ectoenzyme CD39 conversion of extracellular ATP (eATP) to AMP and thus potentially augment eATP–P2-mediated proinflammatory responses. Using syngeneic and humanized tumor models, we contrast the potency and mechanism of anti-CD39 mAbs with other agents targeting the adenosinergic pathway. We demonstrate the critical importance of an eATP–P2X7–ASC–NALP3-inflammasome–IL18 pathway in the antitumor activity mediated by CD39 enzyme blockade, rather than simply reducing adenosine as mechanism of action. Efficacy of anti-CD39 activity was underpinned by CD39 and P2X7 coexpression on intratumor myeloid subsets, an early signature of macrophage depletion, and active IL18 release that facilitated the significant expansion of intratumor effector T cells. More importantly, anti-CD39 facilitated infiltration into T cell–poor tumors and rescued anti–PD-1 resistance. Anti-human CD39 enhanced human T-cell proliferation and Th1 cytokine production and suppressed human B-cell lymphoma in the context of autologous Epstein–Barr virus–specific T-cell transfer.Significance:Overall, these data describe a potent and novel mechanism of action of antibodies that block mouse or human CD39, triggering an eATP–P2X7–inflammasome–IL18 axis that reduces intratumor macrophage number, enhances intratumor T-cell effector function, overcomes anti–PD-1 resistance, and potentially enhances the efficacy of adoptive T-cell transfer.This article is highlighted in the In This Issue feature, p. 1631


  • Top Cited Papers

    Targeting CD39 in cancer

    by Achim K. Moesta, Xian-Yang Li, Mark J. Smyth

    The ATP–adenosine pathway functions as a key modulator of innate and adaptive immunity within the tumour microenvironment. Consequently, multiple clinical strategies are being explored to target this pathway for the treatment of cancer; in particular, recent clinical data with CD73 antagonists and inhibitors of A2A receptors have demonstrated the therapeutic potential of modulating this pathway. Now, inhibitors of the ectonucleotidase CD39, the rate-limiting enzyme in the conversion of ATP to immunomodulatory adenosine, are entering clinical trials. Consequently, there is currently a focus on understanding the impact of CD39 enzymatic function on innate and adaptive immunity and how therapeutic modulation of this pathway alters their functional potential within the tumour microenvironment. Recent findings reveal multipronged mechanisms of action of CD39 antagonism that rely not only on preventing the accumulation of adenosine but also on the stabilization of pro-inflammatory extracellular ATP to restore antitumour immunity. Here, we review the impact of CD39 expression and ectonucleotidase activity on immunity with a focus on the setting of oncology. Additionally, we discuss the implications for immunotherapy strategies targeting CD39, including their inclusion in rational combination therapies.


  • Control of Metastases via Myeloid CD39 and NK Cell Effector Function

    by Juming Yan, Xian-Yang Li, Amelia Roman Aguilera, Christos Xiao, Celia Jacoberger-Foissac, Bianca Nowlan, Simon C. Robson, Courtney Beers, Achim K. Moesta, Nishamol Geetha, et al.

    Natural killer (NK) cell protection from tumor metastases is a critical feature of the host immune response to cancer, but various immunosuppression mechanisms limit NK cell effector function. The ectoenzyme, CD39, expressed on tumor-infiltrating myeloid cells, granulocytes, and lymphocytes, including NK cells, converts extracellular ATP (eATP) into AMP and, thus, potentially suppresses eATP-mediated proinflammatory responses. A CD39-targeting monoclonal antibody (mAb) that inhibits the mouse ectoenzyme CD39 suppressed experimental and spontaneous metastases in a number of different tumor models and displayed superior antimetastatic activity compared with the CD39 inhibitor POM1 and inhibitors and mAbs that block other members of the adenosinergic family (e.g., A2AR and CD73). The antimetastatic activity of anti-CD39 was NK cell and IFNγ dependent, and anti-CD39 enhanced the percentage and quantity of IFNγ produced and CD107a expression in lung-infiltrating NK cells following tumor challenge and anti-CD39 therapy. Using conditional Cd39 gene–targeted mouse strains and adoptive NK cell transfers, we showed that CD39 expressed on bone marrow–derived myeloid cells was essential for anti-CD39′s antimetastatic activity, but NK cell expression of CD39 was not critical. The eATP receptor P2X7 and the NALP3 inflammasome, including downstream IL18, were critical in the mechanism of action of anti-CD39, and the frequency of P2X7 and CD39 coexpressing lung alveolar macrophages was specifically reduced 1 day after anti-CD39 therapy. The data provide a mechanism of action involving NK cells and myeloid cells, and anti-CD39 combined with anti–PD-1, NK cell–activating cytokines IL15 or IL2, or an inhibitor of A2AR to effectively suppress tumor metastases.


  • Top Cited Papers

    Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity

    by Xian-Yang Li, Achim K. Moesta, Christos Xiao, Kyohei Nakamura, Mika Casey, Haiyan Zhang, Jason Madore, Ailin Lepletier, Amelia Roman Aguilera, Ashmitha Sundarrajan, et al.

    We explored the mechanism of action of CD39 antibodies that inhibit ectoenzyme CD39 conversion of extracellular ATP (eATP) to AMP and thus potentially augment eATP–P2-mediated proinflammatory responses. Using syngeneic and humanized tumor models, we contrast the potency and mechanism of anti-CD39 mAbs with other agents targeting the adenosinergic pathway. We demonstrate the critical importance of an eATP–P2X7–ASC–NALP3-inflammasome–IL18 pathway in the antitumor activity mediated by CD39 enzyme blockade, rather than simply reducing adenosine as mechanism of action. Efficacy of anti-CD39 activity was underpinned by CD39 and P2X7 coexpression on intratumor myeloid subsets, an early signature of macrophage depletion, and active IL18 release that facilitated the significant expansion of intratumor effector T cells. More importantly, anti-CD39 facilitated infiltration into T cell–poor tumors and rescued anti–PD-1 resistance. Anti-human CD39 enhanced human T-cell proliferation and Th1 cytokine production and suppressed human B-cell lymphoma in the context of autologous Epstein–Barr virus–specific T-cell transfer. Significance: Overall, these data describe a potent and novel mechanism of action of antibodies that block mouse or human CD39, triggering an eATP–P2X7–inflammasome–IL18 axis that reduces intratumor macrophage number, enhances intratumor T-cell effector function, overcomes anti–PD-1 resistance, and potentially enhances the efficacy of adoptive T-cell transfer. This article is highlighted in the In This Issue feature, p. 1631